Clinical Trial Update: A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for SYHA1815 in unresectable locally advanced or metastatic solid tumors, covering Phase 1 and Phase 2 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Unresectable Carcinoma

Drugs mentioned

• SYHA1815 (SYHA1815)

Snippet

Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd | Conditions: Locally Advanced Unresectable Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN